Patient Test Information

Cystatin C

  • Why Get Tested?

    To assess your kidney function if you have known or suspected kidney disease, but only in specific settings when traditional kidney function tests are misleading

    When To Get Tested?

    When a healthcare practitioner suspects that you may have decreased kidney function, but serum creatinine measurements are not reliable; it may be ordered at regular intervals when you have known kidney dysfunction.

    Sample Required?

    A blood sample drawn from a vein in your arm

    Test Preparation Needed?


  • What is being tested?

    Cystatin C is a relatively small protein that is produced throughout the body by all cells that contain a nucleus and is found in a variety of body fluids, including the blood. It is produced, filtered from the blood by the kidneys, and broken down at a constant rate. This test measures the amount of cystatin C in blood to help evaluate kidney function.

    Cystatin C is filtered out of the blood by the glomeruli, clusters of tiny blood vessels in the kidneys that allow water, dissolved substances, and wastes to pass through their walls while retaining blood cells and larger proteins. What passes through the walls of the glomeruli forms a filtrate fluid. From this fluid, the kidneys reabsorb cystatin C, glucose, and other substances. The remaining fluid and wastes are carried to the bladder and excreted as urine. The reabsorbed cystatin C is then broken down and is not returned to the blood.

    The rate at which the fluid is filtered is called the glomerular filtration rate (GFR). A decline in kidney function leads to decreases in the GFR and to increases in cystatin C and other measures of kidney function, such as creatinine and urea in the blood. The increases in these levels occur because the kidneys are not able to properly filter the blood at a normal rate, causing their accumulation in the blood. On the other hand, improvement in kidney function is expected to lead to increases in GFR, which would cause cystatin C, creatinine, and urea to decline as a result of the kidneys being able to effectively clear them from the blood.

    When the kidneys are functioning normally, concentrations of cystatin C in the blood are stable. However, as kidney function deteriorates, the concentrations begin to rise. This increase in cystatin C occurs as the GFR falls and is often detectable before there is a measurable decrease in kidney function (GFR).

    Because cystatin C levels fluctuate with changes in GFR, there has been interest in the cystatin C test as one method of evaluating kidney function. Tests currently used include creatinine, a byproduct of muscle metabolism that is measured in the blood and urine, blood urea nitrogen (BUN), and eGFR (an estimate of the GFR usually calculated from the blood creatinine level). Unlike creatinine, cystatin C is not significantly affected by muscle mass (hence, sex or age), race, or diet, which has led to the idea that it could be a more reliable marker of kidney function and potentially used to generate a more precise estimate of GFR.

    While there are growing data and literature supporting the use of cystatin C, there is still a degree of uncertainty about when and how it should be used. However, testing is becoming increasingly more available and steps are being taken toward standardizing the calibration of cystatin C results.

  • How is it used?

    A cystatin C test may be used as an alternative to creatinine and creatinine clearance to screen for and monitor kidney dysfunction in those with known or suspected kidney disease. It is most useful in special cases where creatinine measurement could be misleading.

    For example, in those who have liver cirrhosis, are very obese, are malnourished, practice a vegetarian diet, have amputated limbs, or have reduced muscle mass (elderly and children), creatinine measurements may not be reliable. Since creatinine depends on muscle mass, assessment of kidney function may therefore not be accurate in these individuals with abnormally high or low body mass. Cystatin C is not affected by body mass or diet, and hence is a more reliable marker of kidney function than creatinine.

    Measuring cystatin C may also be useful in the early detection of kidney disease when other test results (eGFR, creatinine or urine albumin) may still be normal or borderline and an affected person may have few, if any, symptoms. In this case, the healthcare practitioner may want to confirm if chronic kidney disease is present by measuring cystatin c.

    Researchers are exploring other uses of cystatin C, such as using it alone or in combination with blood creatinine for estimating the glomerular filtration rate (GFR). A recent study found that an equation for eGFR that includes both creatinine and cystatin C was more accurate than one that uses either of these alone and could be used to confirm chronic kidney disease (CKD) in people with an eGFR near 60, the threshold for CKD. In addition to kidney dysfunction, it has been associated with an increased risk of mortality, cardiovascular disease and heart failure in older adults. These equations are currently being validated in different patient populations prior to it being fully implemented into clinical practice.

    Lastly, there is some research suggesting that cystatin C returns to a normal level more quickly than creatinine and could be used to assess kidney function and severity of illness when GFR is rapidly changing in critically ill hospitalized patients.

    When is it ordered?

    Cystatin C is gaining acceptance as studies confirm and define its usefulness, especially as an early, sensitive marker for chronic kidney disease (CKD). It may be ordered when a person has a known or suspected disease that affects or potentially affects kidney function and reduces the rate at which the kidneys filter impurities from the blood, the glomerular filtration rate (GFR).

    It may be ordered when a healthcare practitioner is not satisfied with the results of other tests, such as a creatinine or creatinine clearance, or wants to check for early kidney dysfunction, particularly in the elderly or in sick babies, and/or wants to monitor known impairment over time.

    Research is ongoing to learn more about cystatin C as an indicator of risk of end stage renal disease, heart failure, and death. Studies have also found that, in diverse populations, cystatin C may improve the estimate of GFR when combined in an equation with blood creatinine.

    What does the test result mean?

    A high level of cystatin C in the blood corresponds to a decreased glomerular filtration rate (GFR) and hence to kidney dysfunction.

    Since cystatin C is produced throughout the body at a constant rate and removed and broken down by the kidneys, it should remain at a steady level in the blood if the kidneys are working efficiently and the GFR is normal.

    Recent studies suggest that increased levels of cystatin C may also indicate an increased risk of heart disease, heart failure, and mortality.

    Is there anything else I should know?

    Although cystatin C is less variable and less affected by age, body mass, and diet than creatinine in some individuals, it is not a perfect test and can be affected by a number of drugs and other medical conditions.

    Some studies have reported increased cystatin C levels associated with higher levels of C-reactive protein (CRP) or body mass index (BMI), hyperthyroidism, steroid use, malignant diseases, HIV/AIDS, rheumatic diseases, and certain metabolic conditions such as hyperhomocysteinemia (increased homocysteine). In addition, other studies suggest that cystatin C can be cleared by non-kidney pathways, such as in the gut, and that its levels tend to fluctuate among patients with kidney transplants.

    Can cystatin C be measured in my urine?

    No. Unlike creatinine, cystatin C is reabsorbed from the glomerular filtrate and then metabolized in the kidneys. Under normal conditions, cystatin C is not found at detectable levels in the urine.

    How is an eGFR calculated?

    The most commonly used equation for calculating the eGFR, and the one currently recommended by the National Kidney Foundation (NKF) and KDIGO guidelines for general use, is called the CKD-EPI equation. It requires a person's serum creatinine (and/or serum cystatin c), age, and assigned values based upon sex and race. Researchers are also evaluating the usefulness of a variety of other equations to estimate GFR that combine tests such as a creatinine, BUN, and/or cystatin C.

    How can my actual GFR be determined?

    The best method for directly determining the glomerular filtration rate (GFR) is a procedure called an "inulin clearance." It involves introducing a fluid containing the marker molecule inulin (NOT insulin) into your veins (IV – intravenous infusion) and then collecting timed urine samples over a period of hours. The urine volumes are noted and the inulin in each sample is measured to allow determination of the GFR. This test and other methods of determining GFR, such as those that use radioactive markers, are not routinely ordered and are primarily performed in research settings.

  • View Sources

    Sources Used in Current Review

    2017 review performed by Joshua E Raizman, PhD, FCACB.

    Ebert N, Delanaye P, Shlipak M, Jakob O, Martus P, Bartel J, Gaedeke J, van der Giet M, Schuchardt M, Cavalier E, Schaeffner E. Cystatin C standardization decreases assay variation and improves assessment of glomerular filtration rate. Clin Chim Acta. 2016 May 1;456:115-21.

    Kidney Disease Improving Global Outcomes, KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Available online at Accessed April 2017.

    Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS.; CKD-EPI Investigators Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012 Jul 5;367(1):20-9.

    Waheed S, Matsushita K, Sang Y, Hoogeveen R, Ballantyne C, Coresh J, Astor BC. Combined association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2012 Aug;60(2):207-16.

    Dalcomune DM, Terrão J, Porto ML, Vasquez EC, Baldo MP, Pereira TM. Predictive value of cystatin C for the identification of illness severity in adult patients in a mixed intensive care unit. Clin Biochem. 2016 Jul;49(10-11):762-7.

    Brown CS, Kashani KB, Clain JM, Frazee EN. Cystatin C Falsely Underestimated GFR in a Critically Ill Patient with a New Diagnosis of AIDS. Case Rep Nephrol. 2016;2016:9349280.

    ©2014 National Kidney Foundation. Frequently asked questions about GFR estimates. Available online at Accessed 26/04/2017.

    Sources Used in Previous Reviews

    Thomas, Clayton L., Editor (1997). Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].

    Jeffrey, S. (2006 August 16). Cystatin C May Identify Pre-CKD in Elderly With Normal eGFR. Medscape Medical News [On-line information]. Available online at

    Jeffrey, S. (2005 September 6). Cystatin C is a sensitive marker of prognosis acute heart failure. Medscape Medical News [On-line information]. Available online at

    Shlipak, M. (2005 May 19). Cystatin C and the Risk of Death and Cardiovascular Events among Elderly Persons. NEJM v 352(20) 2049-2060 [On-line journal]. Available online at

    Sarnak, M. (2005 April 5). Cystatin C Concentration as a Risk Factor for Heart Failure in Older Adults. Annals of Internal Medicine v142(7) [On-line information]. Available online at

    Villa, P. et. al. (2005 April). Serum cystatin C concentration as a marker of acute renal dysfunction in critically ill patients. Crit Care. 2005; 9(2): R139-R143 [On-line journal]. Available online at

    Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 328-329.

    Clarke, W. and Dufour, D. R., Editors (© 2006). Contemporary Practice in Clinical Chemistry: AACC Press, Washington, DC. Pp 312.

    Lowry, F. (2009 February 27). Cystatin C, High Levels of Serum Cystatin C and Chronic Kidney Disease Linked to Age-Related Macular Degeneration. Medscape Medical News [On-line information]. Available online at Accessed October 2009.

    Ma, Y-C. et. al. (2008 January 28). Improved GFR Estimation by Combined Creatinine and Cystatin C Measurements. Medscape Today from Kidney International [On-line information]. Available online at Accessed October 2009.

    Craig, R. G. and Hunder, J. M. (2008 October 27). Recent Developments in the Perioperative Management of Adult Patients with Chronic Kidney Disease. Medscape Today from British Journal of Anaesthesia [On-line information]. Available online at Accessed October 2009.

    (2009 January 27). New Equation Accurately Estimates GFR in Children With Kidney Disease. Medscape Today from Reuters Health Information [On-line information]. Available online at Accessed October 2009.

    (Updated 2009 August). Renal Function Markers - Kidney Disease. ARUP Consult. [On-line information]. Available online at Accessed October 2009.

    (April 7, 2009) National Kidney Disease Education Program, Laboratory Professionals: Update on Cystatin C. Available online at Accessed January 2010.

    Henry's Clinical Diagnosis and Management by Laboratory Methods. 21st ed. McPherson R, Pincus M, eds. Philadelphia, PA: Saunders Elsevier: 2007, Pp 153-154.

    Lerma, E. (Updated 2012 May 17). Novel Biomarkers of Renal Function. Medscape Reference [On-line information]. Available online at Accessed July 2013.

    Sinert, R. and Peacock, P. (Updated 2013 June 20). Acute Renal Failure Complications. Medscape Reference [On-line information]. Available online at Accessed July 2013.

    Malone, B. (2012 August 23). Refining the Role of Cystatin C in Estimating GFR New Combined Cystatin C –Creatinine Equation More Accurate. Clinical Laboratory Strategies [On-line information]. Available online at Accessed July 2013.

    (© 1995–2013). Cystatin C with Estimated GFR, Serum. Mayo Clinic Mayo Medical Laboratory Interpretive Handbook [On-line information]. Available online at Accessed July 2013.

    Paxton, A. (2012 September). Cystatin C and creatinine—using both found to be best. CAP Today [On-line information]. Available online through Accessed July 2013.

    Shah, A. (Revised 2013 May). Evaluation of the Renal Patient. Merck Manual for Healthcare Professionals [On-line information]. Available online through Accessed July 2013.

    Pagana, K. D. & Pagana, T. J. (© 2011). Mosby's Diagnostic and Laboratory Test Reference 10th Edition: Mosby, Inc., Saint Louis, MO. Pp 326-333.

    Clarke, W., Editor (© 2011). Contemporary Practice in Clinical Chemistry 2nd Edition: AACC Press, Washington, DC. Pp 363-366.

    McPherson, R. and Pincus, M. (© 2011). Henry's Clinical Diagnosis and Management by Laboratory Methods 22nd Edition: Elsevier Saunders, Philadelphia, PA. Pp 177.

    Zhou H, Hewitt SM, Yuen PS, Star RA. Acute Kidney Injury Biomarkers - Needs, Present Status, and Future Promise. Nephrol Self Assess Program. Mar 2006;5(2):63-71. Available online at Accessed August 2013.

    National Kidney and Urologic Diseases Information Clearinghouse. Kidney Disease Research Updates, Winter 2013. NIH-funded Study Finds More Precise Way to Estimate Kidney Function. Available online at Accessed October 2013.

    National Kidney Foundation. Cystatin C: What is its role in estimating GFR? Available online at Accessed October 2013.

    National Kidney Disease Education Program. Estimating GFR. Available online at Accessed October 2013.

    National Kidney Disease Education Program. Update on Cystatin C: Cystatin C Standardization (Update as of July 2010). Available online at Accessed October 2013.

    UCSF (Karin Rush-Monroe on September 04, 2013). Kidney Function Can Be Assessed by Measuring Cystatin C in Blood. Available online at Accessed October 2013.

    Shlipak MG et al. Cystatin C versus Creatinine in Determining Risk Based on Kidney Function. N Engl J Med 2013; 369:932-943, September 5, 2013. Available online at Accessed October 2013.